Kittisak Kaewchalun
Shares of GeoVax (NASDAQ:GOVX) shot up 50% in mid-afternoon buying and selling Tuesday amid information that the US authorities plans to fund a Part 2b research of the corporate’s next-generation COVID-19 vaccine.
GeoVax mentioned in an SEC submitting that the randomized, double-blinded research will enroll 10,000 individuals and be absolutely funded by the Biomedical Superior Analysis and Growth Authority, or BARDA. The research will examine the efficacy, security and immunogenicity of GeoVax’s duel-antigen vaccine GEO-CM04S1 with an FDA-approved mRNA COVID-19 vaccine.
Beneath the settlement, BARDA will award GeoVax as much as $45M for the manufacturing of scientific supplies and help for the Part 2b research. The federal government will even present round $343M for a scientific analysis group to conduct the scientific trial.
Presently, the FDA has accredited two mRNA COVID-19 vaccines, Pfizer (PFE) and BioNTech’s (BNTX) Comirnaty and Moderna’s (MRNA) Spikevax.